Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, an...

Source: Allergy, Asthma and Clinical Immunology - May 13, 2023 Category: Allergy & Immunology Authors: Nami Masumoto, Chiyako Oshikata, Ryo Nakadegawa, Yuto Motobayashi, Reeko Osada, Saki Manabe, Takeshi Kaneko and Naomi Tsurikisawa Tags: Research Source Type: research